<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/29E60961-02D0-4C26-8D0B-D1C83013860B"><gtr:id>29E60961-02D0-4C26-8D0B-D1C83013860B</gtr:id><gtr:name>Crystec Limited</gtr:name><gtr:address><gtr:line1>NORCROFT BUILDING, , RICHMOND ROAD</gtr:line1><gtr:city>BRADFORD</gtr:city><gtr:postCode>BD7 1DP</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/29E60961-02D0-4C26-8D0B-D1C83013860B" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>29E60961-02D0-4C26-8D0B-D1C83013860B</gtr:id><gtr:name>Crystec Limited</gtr:name><gtr:address><gtr:line1>NORCROFT BUILDING, , RICHMOND ROAD</gtr:line1><gtr:city>BRADFORD</gtr:city><gtr:postCode>BD7 1DP</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>100000.0</gtr:offerGrant><gtr:projectCost>174213.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4164F421-2DDC-40BE-8BC0-3283D6C528BB"><gtr:id>4164F421-2DDC-40BE-8BC0-3283D6C528BB</gtr:id><gtr:firstName>Catherine</gtr:firstName><gtr:surname>Hunter</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710229"><gtr:id>CF536984-2889-4F39-B972-BFC9B5BCD11C</gtr:id><gtr:title>A Novel Therapy for Treatment of Urinary Incontinence</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710229</gtr:grantReference><gtr:abstractText>CrystecPharma is a crystal and particle engineering company enabling the development of new and more effective medicines. CrystecPharma applies the latest supercritical fluid (SCF) technology to create drug particles which dissolve more quickly and can be delivered via alternative routes of administration. Although a relatively young company the team have over 70 years of experience of SCF between them and Chief Scientist, Professor Peter York, is the founder of SCF technology in this field.
This project aims to develop novel particles with rapid action in patients with urinary incontinence. Although 500 million people worldwide suffer from urinary incontinence the disease remains very poorly treated. Incontinence takes several forms, urge (a sudden onset of need to urinate), stress (urination as a consequence of exertion e.g. coughing), and mixed (a combination of both types). Incontinence is especially prevalent (up to 26%) in adult women and of these, approximately 47% will suffer from urge or mixed urinary incontinence.
This project aims to prove the concept of a novel therapy to treat urge and mixed incontinence in a more manageable way. The treatment will enable sufferers to take a medicine for fast uptake in the circulation and rapid bladder control. It is hoped that patients will be able to take the medicine immediately upon feeling an urge, providing control before the onset of leakage, or prophylactically when required. Current therapies used in this area do not act rapidly enough to alleviate the symptoms before involuntary urination occurs. To achieve short-term bladder control, these drugs are often used at doses which cause many side effects. It is hoped a treatment such as this will revolutionise the treatment of this disease and improve the quality of life for incontinence patients.</gtr:abstractText><gtr:fund><gtr:end>2014-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>100000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710229</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>